SS RELEASES Crown Bioscience Enables Secure Data Real time Access with the Release of Client Facing Portal
(Santa Clara, Calif., March 9, 2016) — Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology and metabolic disease research, has expedited their access to study data with the release of a new, secure online data portal.
The proprietary, client data portal was created in alignment with an ongoing strategic initiative to utilize digital platforms to drive increased customer value. Developed internally by Crown Bio’s bioInformatics group, the platform provides real-time research results allowing clients continuous access to their data.
This innovative tool enables client to perform data manipulation online, or download the study results in multiple formats. Clients may also import their data into their systems and perform further analysis within their chosen application.
“We live in an era where technology allows people to access data when and where they choose. At CrownBio, we want to bring this high-speed standard to our clients in a secure and user-friendly manner.” stated Laurie Heilmann, SVP of Global Strategy, Marketing and Business Development. Heilmann continued, “We understand how important the data is to our clients; and therefore, we have developed a portal that will permit our clients to have secure access to their project updates and datasets at any time.”
This first release of the data portal contains essential filtering capabilities. Future releases will add to the core feature set and be driven entirely by a customer advisory and governance panel.
“This governance group will shape the development of the portal, ensuring that our digital tools reflect the needs of our customers and solve real-world challenges.” Commented Gavin Cooper, Executive Director of Marketing.
For more information on CrownBio’s commitment to furthering the field of oncology and metabolic disease drug discovery, visit https://www.crownbio.com
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
Contact details
-
- Louise Stenson
-
Crown Bioscience Company Inquiries
Communications Manager - louise.stenson@crownbio.com
Related topics
Related news
Crown Bioscience Achieves CAP 15189 Accreditation; ISO 15189 Standard for Quality Medical Laboratory Services
Crown Bioscience today announced the dual attainment of College of American Pathologists (CAP) accreditations for its medical laboratory services.
Crown Bioscience Introduces OrganoidXplore: Revolutionizing Cancer Research with Rapid Large-scale Organoid Drug Scre...
Crown Bioscience has launched OrganoidXplore, a revolutionary platform for large-scale screening of patient-derived organoids that accelerates preclinical oncology drug discovery. The platform repl...
Indivumed Services’ Hamburg Site Receives College of American Pathologists (CAP) Accreditation
Indivumed Services GmbH, a Crown Bioscience company, has received laboratory accreditation from the College of American Pathologists (CAP), highlighting its commitment to excellence in laboratory s...
Crown Bioscience Enables HanX Biopharmaceutical to Progress HX009 to Clinical Trials
Crown Bioscience collaborates with HanX Biopharmaceutical, enabling the progression of HX009 to clinical trials for the treatment of lymphoma. The study demonstrates the efficacy of HX009 in target...
Crown Bioscience Announces Transaction Closing of Indivumed’s Service Business and Supporting Biobank
Crown Bioscience, a global contract research organization (CRO) and JSR Life Sciences company, announced today that it has completed its acquisition of the IndivuServ business unit of Indivumed Gmb...